JP4284177B2 - 脳卒中および他の虚血性症状の治療用ｈｄｌ - Google Patents
脳卒中および他の虚血性症状の治療用ｈｄｌ Download PDFInfo
- Publication number
- JP4284177B2 JP4284177B2 JP2003522564A JP2003522564A JP4284177B2 JP 4284177 B2 JP4284177 B2 JP 4284177B2 JP 2003522564 A JP2003522564 A JP 2003522564A JP 2003522564 A JP2003522564 A JP 2003522564A JP 4284177 B2 JP4284177 B2 JP 4284177B2
- Authority
- JP
- Japan
- Prior art keywords
- hdl
- use according
- ischemia
- administered
- rhdl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 230000000302 ischemic effect Effects 0.000 title claims description 13
- 208000006011 Stroke Diseases 0.000 title abstract description 24
- 238000001802 infusion Methods 0.000 claims abstract description 11
- 238000001990 intravenous administration Methods 0.000 claims abstract description 9
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 62
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 62
- 208000028867 ischemia Diseases 0.000 claims description 17
- 150000002632 lipids Chemical class 0.000 claims description 12
- 206010063837 Reperfusion injury Diseases 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 9
- 230000010410 reperfusion Effects 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000007592 Apolipoproteins Human genes 0.000 claims description 6
- 108010071619 Apolipoproteins Proteins 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 4
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 108010080283 Pre-beta High-Density Lipoproteins Proteins 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 150000001840 cholesterol esters Chemical class 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 208000037816 tissue injury Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 12
- 208000037906 ischaemic injury Diseases 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 31
- 210000004556 brain Anatomy 0.000 description 17
- 210000003657 middle cerebral artery Anatomy 0.000 description 14
- 230000001052 transient effect Effects 0.000 description 10
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 9
- 206010061216 Infarction Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000007574 infarction Effects 0.000 description 9
- 206010028851 Necrosis Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 8
- 230000017074 necrotic cell death Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 7
- 206010049771 Shock haemorrhagic Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008753 endothelial function Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003492 excitotoxic effect Effects 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 231100000318 excitotoxic Toxicity 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000000260 hypercholesteremic effect Effects 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- -1 adhesion molecules Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000006493 arterial relaxation Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 206010007687 Carotid artery stenosis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010073708 Obstructive shock Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 239000012659 cardioprotective agent Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 208000006170 carotid stenosis Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31360501P | 2001-08-20 | 2001-08-20 | |
| EP01120026A EP1285662A1 (en) | 2001-08-20 | 2001-08-20 | Reconstituted HDL for the treatment of stroke and ischemic conditions |
| PCT/EP2002/009294 WO2003018047A2 (en) | 2001-08-20 | 2002-08-20 | Hdl for the treatment of stroke and other ischemic conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005501110A JP2005501110A (ja) | 2005-01-13 |
| JP2005501110A5 JP2005501110A5 (https=) | 2005-12-22 |
| JP4284177B2 true JP4284177B2 (ja) | 2009-06-24 |
Family
ID=26076691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003522564A Expired - Fee Related JP4284177B2 (ja) | 2001-08-20 | 2002-08-20 | 脳卒中および他の虚血性症状の治療用ｈｄｌ |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20040266660A1 (https=) |
| EP (1) | EP1425031B8 (https=) |
| JP (1) | JP4284177B2 (https=) |
| AT (1) | ATE396736T1 (https=) |
| AU (1) | AU2002340825B2 (https=) |
| CA (1) | CA2457840C (https=) |
| DE (1) | DE60226881D1 (https=) |
| ES (1) | ES2304452T3 (https=) |
| WO (1) | WO2003018047A2 (https=) |
| ZA (1) | ZA200401360B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0310100A (pt) * | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2007000924A1 (ja) * | 2005-06-28 | 2007-01-04 | Osaka University | プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法 |
| US20070110751A1 (en) * | 2005-10-25 | 2007-05-17 | Maclellan Robb | Compositions and methods for reducing infarct size |
| JP5601750B2 (ja) * | 2007-03-01 | 2014-10-08 | シーエスエル、リミテッド | 糖尿病患者の内皮機能異常の治療 |
| AU2007200908B2 (en) * | 2007-03-01 | 2012-08-16 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| WO2010151096A1 (en) | 2009-06-25 | 2010-12-29 | Tetra, Sia | Therapeutic combinations of nicotinic acid and meldonium |
| JP2012532919A (ja) * | 2009-07-16 | 2012-12-20 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 治療因子を含むｈｄｌおよび治療における使用 |
| US12419839B2 (en) | 2009-10-09 | 2025-09-23 | Signablok, Inc. | Methods and compositions for targeted delivery of protein fragments |
| US10525152B2 (en) | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
| US20120189612A1 (en) * | 2011-01-25 | 2012-07-26 | The Cleveland Clinic Foundation | Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy |
| HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| AU2012236889A1 (en) * | 2011-03-25 | 2013-05-09 | The Trustees Of Columbia University In The City Of New York | Pegylated human HDL particle and process for production thereof |
| EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| CA2947127A1 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| ES2984286T3 (es) | 2017-08-10 | 2024-10-29 | Abionyx Pharma Sa | Apómeros |
| EP3668600B1 (en) | 2017-08-10 | 2024-05-15 | Abionyx Pharma SA | Cargomers |
| WO2021191266A1 (en) | 2020-03-25 | 2021-09-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosolization of hdl for the treatment of lung infections |
| MX2022012969A (es) | 2020-04-16 | 2022-11-09 | Abionyx Pharma Sa | Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos. |
| IL301769A (en) | 2020-10-01 | 2023-05-01 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| US12599677B2 (en) | 2020-10-05 | 2026-04-14 | Northwestern University | Targeted PH sensitive liposomes |
| MX2023012223A (es) | 2021-04-15 | 2023-10-26 | Abionyx Pharma Sa | Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos. |
| AU2023250345A1 (en) | 2022-04-06 | 2024-11-14 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| CN119317440A (zh) | 2022-04-06 | 2025-01-14 | 阿比奥尼克斯制药公司 | 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法 |
| JP2025519606A (ja) | 2022-06-10 | 2025-06-26 | アビオニクス ファーマ エスエー | 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法 |
| IL317448A (en) | 2022-06-10 | 2025-02-01 | Abionyx Pharma Sa | Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins |
| IL322074A (en) | 2023-01-13 | 2025-09-01 | Abionyx Pharma Sa | Treatment using a lipid-binding protein molecule |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| WO2026008645A1 (en) | 2024-07-02 | 2026-01-08 | Institut National de la Santé et de la Recherche Médicale | Aerosolization of apolipoprotein a1 nanoparticles enriched with alpha-1-antitrypsin for the treatment of pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
| GB9919713D0 (en) * | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| AUPQ429399A0 (en) | 1999-11-26 | 1999-12-23 | Heart Research Institute, The | Oxidized apolipoproteins and methods of use |
-
2002
- 2002-08-20 DE DE60226881T patent/DE60226881D1/de not_active Expired - Lifetime
- 2002-08-20 AU AU2002340825A patent/AU2002340825B2/en not_active Ceased
- 2002-08-20 JP JP2003522564A patent/JP4284177B2/ja not_active Expired - Fee Related
- 2002-08-20 EP EP02774525A patent/EP1425031B8/en not_active Expired - Lifetime
- 2002-08-20 WO PCT/EP2002/009294 patent/WO2003018047A2/en not_active Ceased
- 2002-08-20 CA CA2457840A patent/CA2457840C/en not_active Expired - Fee Related
- 2002-08-20 AT AT02774525T patent/ATE396736T1/de active
- 2002-08-20 ES ES02774525T patent/ES2304452T3/es not_active Expired - Lifetime
- 2002-08-20 US US10/487,224 patent/US20040266660A1/en not_active Abandoned
-
2004
- 2004-02-19 ZA ZA2004/01360A patent/ZA200401360B/en unknown
-
2007
- 2007-05-04 US US11/744,780 patent/US7491693B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1425031B1 (en) | 2008-05-28 |
| ZA200401360B (en) | 2005-08-31 |
| ES2304452T3 (es) | 2008-10-16 |
| WO2003018047A2 (en) | 2003-03-06 |
| CA2457840C (en) | 2011-10-11 |
| CA2457840A1 (en) | 2003-03-06 |
| DE60226881D1 (de) | 2008-07-10 |
| JP2005501110A (ja) | 2005-01-13 |
| US20080108550A1 (en) | 2008-05-08 |
| ATE396736T1 (de) | 2008-06-15 |
| EP1425031A2 (en) | 2004-06-09 |
| WO2003018047A3 (en) | 2004-01-29 |
| EP1425031B8 (en) | 2008-09-03 |
| US20040266660A1 (en) | 2004-12-30 |
| AU2002340825B2 (en) | 2007-07-05 |
| HK1064304A1 (en) | 2005-01-28 |
| US7491693B2 (en) | 2009-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4284177B2 (ja) | 脳卒中および他の虚血性症状の治療用ｈｄｌ | |
| AU2002340825A1 (en) | HDL for the treatment of stroke and other ischemic conditions | |
| JP3559280B2 (ja) | オメガ−３−脂肪酸の用法 | |
| US6166077A (en) | Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1 | |
| JPH05506034A (ja) | アクチン結合性化合物の療法的使用 | |
| Tepes et al. | Stable gastric pentadecapeptide BPC 157 therapy for primary abdominal compartment syndrome in rats | |
| Li et al. | Protective effect of GSK-3β/Nrf2 mediated by dimethyl fumarate in middle cerebral artery embolization reperfusion rat model | |
| Dobosz et al. | Organ microcirculatory disturbances in experimental acute pancreatitis: A role of nitric oxide | |
| CN1203861C (zh) | 含有人参皂甙Rb1的脑血管再生/再造促进剂和继发性神经组织变性抑制剂 | |
| Cuevas et al. | Systemic administration of acidic fibroblast growth factor ameliorates the ischemic injury of the retina in rats | |
| Abolhasanpour et al. | Cerebrolysin use in stroke and spinal cord injury: review of the literature and outcomes | |
| HK1064304B (en) | Hdl for the treatment of stroke and other ischemic conditions | |
| CA2304956C (en) | Pharmaceutical composition for preventing or treating ischemic diseases | |
| NO321126B1 (no) | Salt av et BPC (Body protection compound) "kroppsbeskyttelsesforbindelse"-peptid, omfattende 8 aminosyrerester, kompatibelt, lagringsstabilt, farmasoytisk preparat, diagnostisk lagringsstabilt preparat, anvendelser og fremgangsmater derav. | |
| TWI311485B (en) | Reconstituted hdl for the treatment of stroke and ischemic conditions | |
| RU2085200C1 (ru) | Способ предоперационного лечения рака прямой кишки | |
| EP1285662A1 (en) | Reconstituted HDL for the treatment of stroke and ischemic conditions | |
| AU706088B2 (en) | Transferrin compositions to alleviate the side effects of cytotoxic drugs | |
| CN103393740B (zh) | 乳香提取物在防治心脑血管或肝肾损伤中应用 | |
| Thorp et al. | Ozone preconditioning: Waking up the dragon | |
| Kaya et al. | Intraarticular Ankaferd blood stopper application increases cartilage degeneration: an experimental study | |
| CN101229366A (zh) | 成纤维细胞生长因子在制备促进血管生成药物中的应用 | |
| RU2826364C1 (ru) | Способ лечения черепно-мозговой травмы и средство для его осуществления | |
| JP2006169128A (ja) | 熱傷治療剤 | |
| JP3691533B2 (ja) | 抗動脈硬化ペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050427 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080715 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081009 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090115 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090303 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090323 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4284177 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120327 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130327 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130327 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140327 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |